Meliterix 14 mg apvalkotās tabletes Letonya - Letonca - Zāļu valsts aģentūra

meliterix 14 mg apvalkotās tabletes

norameda uab, lithuania - teriflunomīds - apvalkotā tablete - 14 mg

Imaplix 10 mg + 20 mg + 30 mg apvalkotās tabletes Letonya - Letonca - Zāļu valsts aģentūra

imaplix 10 mg + 20 mg + 30 mg apvalkotās tabletes

norameda uab, lithuania - apremilasts - apvalkotā tablete - 10 mg + 20 mg + 30 mg

Imaplix 30 mg apvalkotās tabletes Letonya - Letonca - Zāļu valsts aģentūra

imaplix 30 mg apvalkotās tabletes

norameda uab, lithuania - apremilasts - apvalkotā tablete - 30 mg

Adepend 50 mg apvalkotās tabletes Letonya - Letonca - Zāļu valsts aģentūra

adepend 50 mg apvalkotās tabletes

norameda uab, lithuania - naltreksona hidrohlorīds - apvalkotā tablete - 50 mg

Breso 50 mikrogrami/izsmidzinājumā deguna aerosols, suspensija Letonya - Letonca - Zāļu valsts aģentūra

breso 50 mikrogrami/izsmidzinājumā deguna aerosols, suspensija

norameda uab, lithuania - mometazona furoāts - deguna aerosols, suspensija - 50 µg/izsmidzinājumā

Lebsanan 1 mg/g ziede Letonya - Letonca - Zāļu valsts aģentūra

lebsanan 1 mg/g ziede

norameda uab, lithuania - takrolims - ziede - 1 mg/g

Libtayo Avrupa Birliği - Letonca - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, švamšā šūna - antineoplastiski līdzekļi - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Boflox flavour Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

boflox flavour

livisto int'l, s.l., spānija - marbofloxacin - tabletes - 20 mg - kaķi; suņi

Boflox flavour Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

boflox flavour

livisto int'l, s.l., spānija - marbofloxacin - tabletes - 80 mg - suņi

Caremast vet Letonya - Letonca - Pārtikas un veterinārais dienests, Zemkopības ministrija

caremast vet

vetcare oy, somija - benzylpenicillinum procainum monohydricus - suspensija ievadīšanai tesmenī - 600 mg - laktējošas govis